Estrogen-dependent regulation of Eg5 in breast cancer cells

Maricarmen D. Planas-Silva, Irina Filatova

Research output: Contribution to journalArticle

Abstract

HsEg5 (Eg5) is a kinesin required for proper execution of mitosis. Several compounds that specifically block Eg5 are in clinical development and have the potential to be used in the treatment of breast cancer. In this study, we investigated the interaction between Eg5 and estrogen receptor signaling. We observed decreased Eg5 expression after treatment of estrogen receptor-positive human breast cancer MCF-7 cells with the estrogen receptor downregulator fulvestrant. Downregulation of Eg5 expression in response to fulvestrant was also observed in another estrogen receptor-positive cell line ZR-75, but not in the estrogen receptor-negative breast cancer cell line MDA-231. Moreover, in MCF-7 cells previously arrested in the G0/G1 phase of the cell cycle by fulvestrant, addition of estrogen increased Eg5 expression. This upregulation correlated with progression through S-phase. Nevertheless, the effect of fulvestrant in Eg5 expression could not be explained solely by cell cycle arrest, because treatments that blocked cell cycle progression did not consistently decrease Eg5 expression. Pharmacological inhibition of Eg5 function, with either S-trityl-L-cysteine or monastrol, prevented growth of estrogen-treated MCF-7 cells with an IC50 of 0.46 and 29.71 μmol/l, respectively. Simultaneous inhibition of estrogen receptor function with fulvestrant increased the IC50 for S-trityl-L-cysteine to 2.30 μmol/l and for monastrol to 112.69 μmol/l. Our results suggest that pharmacological inhibition of Eg5 may be an effective treatment for estrogen receptor-positive breast cancer, even without concomitant hormonal therapy.

Original languageEnglish (US)
Pages (from-to)773-779
Number of pages7
JournalAnti-Cancer Drugs
Volume18
Issue number7
DOIs
StatePublished - Aug 1 2007
Externally publishedYes

Fingerprint

Estrogen Receptors
Estrogens
Breast Neoplasms
3-tritylthio-L-alanine
MCF-7 Cells
Inhibitory Concentration 50
Cell Cycle
Pharmacology
Cell Line
Kinesin
Cell Cycle Resting Phase
G1 Phase
Cell Cycle Checkpoints
S Phase
Mitosis
Up-Regulation
Down-Regulation
fulvestrant
Growth

Keywords

  • Breast cancer
  • Cell cycle
  • Eg5
  • Estrogen receptor
  • Kinesin

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Estrogen-dependent regulation of Eg5 in breast cancer cells. / Planas-Silva, Maricarmen D.; Filatova, Irina.

In: Anti-Cancer Drugs, Vol. 18, No. 7, 01.08.2007, p. 773-779.

Research output: Contribution to journalArticle

Planas-Silva, Maricarmen D. ; Filatova, Irina. / Estrogen-dependent regulation of Eg5 in breast cancer cells. In: Anti-Cancer Drugs. 2007 ; Vol. 18, No. 7. pp. 773-779.
@article{0bbc610565d4434aa1457fa42dfdd142,
title = "Estrogen-dependent regulation of Eg5 in breast cancer cells",
abstract = "HsEg5 (Eg5) is a kinesin required for proper execution of mitosis. Several compounds that specifically block Eg5 are in clinical development and have the potential to be used in the treatment of breast cancer. In this study, we investigated the interaction between Eg5 and estrogen receptor signaling. We observed decreased Eg5 expression after treatment of estrogen receptor-positive human breast cancer MCF-7 cells with the estrogen receptor downregulator fulvestrant. Downregulation of Eg5 expression in response to fulvestrant was also observed in another estrogen receptor-positive cell line ZR-75, but not in the estrogen receptor-negative breast cancer cell line MDA-231. Moreover, in MCF-7 cells previously arrested in the G0/G1 phase of the cell cycle by fulvestrant, addition of estrogen increased Eg5 expression. This upregulation correlated with progression through S-phase. Nevertheless, the effect of fulvestrant in Eg5 expression could not be explained solely by cell cycle arrest, because treatments that blocked cell cycle progression did not consistently decrease Eg5 expression. Pharmacological inhibition of Eg5 function, with either S-trityl-L-cysteine or monastrol, prevented growth of estrogen-treated MCF-7 cells with an IC50 of 0.46 and 29.71 μmol/l, respectively. Simultaneous inhibition of estrogen receptor function with fulvestrant increased the IC50 for S-trityl-L-cysteine to 2.30 μmol/l and for monastrol to 112.69 μmol/l. Our results suggest that pharmacological inhibition of Eg5 may be an effective treatment for estrogen receptor-positive breast cancer, even without concomitant hormonal therapy.",
keywords = "Breast cancer, Cell cycle, Eg5, Estrogen receptor, Kinesin",
author = "Planas-Silva, {Maricarmen D.} and Irina Filatova",
year = "2007",
month = "8",
day = "1",
doi = "10.1097/CAD.0b013e3280a02f2b",
language = "English (US)",
volume = "18",
pages = "773--779",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Estrogen-dependent regulation of Eg5 in breast cancer cells

AU - Planas-Silva, Maricarmen D.

AU - Filatova, Irina

PY - 2007/8/1

Y1 - 2007/8/1

N2 - HsEg5 (Eg5) is a kinesin required for proper execution of mitosis. Several compounds that specifically block Eg5 are in clinical development and have the potential to be used in the treatment of breast cancer. In this study, we investigated the interaction between Eg5 and estrogen receptor signaling. We observed decreased Eg5 expression after treatment of estrogen receptor-positive human breast cancer MCF-7 cells with the estrogen receptor downregulator fulvestrant. Downregulation of Eg5 expression in response to fulvestrant was also observed in another estrogen receptor-positive cell line ZR-75, but not in the estrogen receptor-negative breast cancer cell line MDA-231. Moreover, in MCF-7 cells previously arrested in the G0/G1 phase of the cell cycle by fulvestrant, addition of estrogen increased Eg5 expression. This upregulation correlated with progression through S-phase. Nevertheless, the effect of fulvestrant in Eg5 expression could not be explained solely by cell cycle arrest, because treatments that blocked cell cycle progression did not consistently decrease Eg5 expression. Pharmacological inhibition of Eg5 function, with either S-trityl-L-cysteine or monastrol, prevented growth of estrogen-treated MCF-7 cells with an IC50 of 0.46 and 29.71 μmol/l, respectively. Simultaneous inhibition of estrogen receptor function with fulvestrant increased the IC50 for S-trityl-L-cysteine to 2.30 μmol/l and for monastrol to 112.69 μmol/l. Our results suggest that pharmacological inhibition of Eg5 may be an effective treatment for estrogen receptor-positive breast cancer, even without concomitant hormonal therapy.

AB - HsEg5 (Eg5) is a kinesin required for proper execution of mitosis. Several compounds that specifically block Eg5 are in clinical development and have the potential to be used in the treatment of breast cancer. In this study, we investigated the interaction between Eg5 and estrogen receptor signaling. We observed decreased Eg5 expression after treatment of estrogen receptor-positive human breast cancer MCF-7 cells with the estrogen receptor downregulator fulvestrant. Downregulation of Eg5 expression in response to fulvestrant was also observed in another estrogen receptor-positive cell line ZR-75, but not in the estrogen receptor-negative breast cancer cell line MDA-231. Moreover, in MCF-7 cells previously arrested in the G0/G1 phase of the cell cycle by fulvestrant, addition of estrogen increased Eg5 expression. This upregulation correlated with progression through S-phase. Nevertheless, the effect of fulvestrant in Eg5 expression could not be explained solely by cell cycle arrest, because treatments that blocked cell cycle progression did not consistently decrease Eg5 expression. Pharmacological inhibition of Eg5 function, with either S-trityl-L-cysteine or monastrol, prevented growth of estrogen-treated MCF-7 cells with an IC50 of 0.46 and 29.71 μmol/l, respectively. Simultaneous inhibition of estrogen receptor function with fulvestrant increased the IC50 for S-trityl-L-cysteine to 2.30 μmol/l and for monastrol to 112.69 μmol/l. Our results suggest that pharmacological inhibition of Eg5 may be an effective treatment for estrogen receptor-positive breast cancer, even without concomitant hormonal therapy.

KW - Breast cancer

KW - Cell cycle

KW - Eg5

KW - Estrogen receptor

KW - Kinesin

UR - http://www.scopus.com/inward/record.url?scp=34250889281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250889281&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3280a02f2b

DO - 10.1097/CAD.0b013e3280a02f2b

M3 - Article

C2 - 17581299

AN - SCOPUS:34250889281

VL - 18

SP - 773

EP - 779

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 7

ER -